Positive trial results for dexamethasone in treating COVID-19 patients have been welcomed by the off-patent industry as demonstrating the potential for repurposing existing generic medicines to help in the fight against the coronavirus pandemic.
With the World Health Organization citing the results from the UK’s “RECOVERY” – or Randomized Evaluation of COVID-19 Therapy – trial as demonstrating the anti-inflammatory drug to be “the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” off-patent industry leaders have not only praised the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?